DekaBank Deutsche Girozentrale
RAPT

DekaBank Deutsche Girozentrale’s RAPT Therapeutics RAPT Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,125
Closed -$152K – 1307
2023
Q1 		$152K Hold
1,125
– – ﹤0.01% 1220
2022
Q4 		$169K Hold
1,125
– – ﹤0.01% 1244
2022
Q3 		$217K Hold
1,125
– – ﹤0.01% 1212
2022
Q2 		$164K Hold
1,125
– – ﹤0.01% 1222
2022
Q1 		$196K Buy
1,125
+100
+10% +$18.9K ﹤0.01% 1214
2021
Q4 		$292K Buy
1,025
+25
+3% +$6.68K ﹤0.01% 1202
2021
Q3 		$254K Hold
1,000
– – ﹤0.01% 1163
2021
Q2 		$260K Hold
1,000
– – ﹤0.01% 1172
2021
Q1 		$172K Hold
1,000
– – ﹤0.01% 1209
2020
Q4 		$157K Buy
+1,000
New +$217K ﹤0.01% 1212

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

DekaBank Deutsche Girozentrale's RAPT Position: Q2 2023 in Review

DekaBank Deutsche Girozentrale sold out of RAPT Therapeutics (RAPT) in Q2 2023, closing a stake of 1,125 shares — an estimated $152K sold.

DekaBank Deutsche Girozentrale first reported a position in RAPT in Q4 2020 and held it in 10 quarters. The position peaked at $292K in Q4 2021. 98 funds tracked by Wall St. Rank hold RAPT as of Q2 2023.

  • DekaBank Deutsche Girozentrale reported no remaining RAPT Therapeutics position as of Q2 2023 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 1,125 RAPT Therapeutics shares in Q2 2023, an estimated $152K.
  • DekaBank Deutsche Girozentrale first reported a position in RAPT Therapeutics in Q4 2020 and held it in 10 quarters.
  • DekaBank Deutsche Girozentrale's RAPT Therapeutics position peaked at $292K in Q4 2021.
  • 98 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2023.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2023, filed 25 Jul 2023.